Direct oral anticoagulants in pediatric venous thromboembolism: Review of approved products rivaroxaban and dabigatran

Venous thromboembolism is a major hospital acquired complication in the pediatric population over the last two-decades, with a 130% increase in the past decade. Direct oral anticoagulants (DOACs) are a newer class of anticoagulant medication for the treatment and prophylaxis of VTEs that provide the...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Ghafry, Maha, Sharathkumar, Anjali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pediatrics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606656/
https://www.ncbi.nlm.nih.gov/pubmed/36313874
http://dx.doi.org/10.3389/fped.2022.1005098

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606656/
https://www.ncbi.nlm.nih.gov/pubmed/36313874
http://dx.doi.org/10.3389/fped.2022.1005098

Ejemplares similares